This company has been marked as potentially delisted and may not be actively trading. Champions Oncology (CSBR) Competitors Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipShort InterestSustainabilityTrendsBuy This Stock CSBR vs. TRML, ORKA, SVRA, RIGL, HRTX, AQST, NKTR, CBIO, ALT, and NATRShould you be buying Champions Oncology stock or one of its competitors? The main competitors of Champions Oncology include Tourmaline Bio (TRML), Oruka Therapeutics (ORKA), Savara (SVRA), Rigel Pharmaceuticals (RIGL), Heron Therapeutics (HRTX), Aquestive Therapeutics (AQST), Nektar Therapeutics (NKTR), Crescent Biopharma (CBIO), Altimmune (ALT), and Nature's Sunshine Products (NATR). These companies are all part of the "med - drugs" industry. Champions Oncology vs. Its Competitors Tourmaline Bio Oruka Therapeutics Savara Rigel Pharmaceuticals Heron Therapeutics Aquestive Therapeutics Nektar Therapeutics Crescent Biopharma Altimmune Nature's Sunshine Products Champions Oncology (NASDAQ:CSBR) and Tourmaline Bio (NASDAQ:TRML) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, analyst recommendations, media sentiment, dividends, profitability and risk. Does the media refer more to CSBR or TRML? In the previous week, Champions Oncology had 21 more articles in the media than Tourmaline Bio. MarketBeat recorded 22 mentions for Champions Oncology and 1 mentions for Tourmaline Bio. Champions Oncology's average media sentiment score of 1.04 beat Tourmaline Bio's score of 0.00 indicating that Champions Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Champions Oncology 15 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Tourmaline Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts prefer CSBR or TRML? Champions Oncology currently has a consensus price target of $12.00, suggesting a potential upside of 42.69%. Tourmaline Bio has a consensus price target of $49.33, suggesting a potential upside of 203.03%. Given Tourmaline Bio's higher possible upside, analysts clearly believe Tourmaline Bio is more favorable than Champions Oncology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Champions Oncology 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Tourmaline Bio 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is CSBR or TRML more profitable? Champions Oncology has a net margin of 10.97% compared to Tourmaline Bio's net margin of 0.00%. Champions Oncology's return on equity of 656.65% beat Tourmaline Bio's return on equity.Company Net Margins Return on Equity Return on Assets Champions Oncology10.97% 656.65% 24.04% Tourmaline Bio N/A -26.75%-26.11% Do insiders & institutionals have more ownership in CSBR or TRML? 41.3% of Champions Oncology shares are held by institutional investors. Comparatively, 91.9% of Tourmaline Bio shares are held by institutional investors. 47.0% of Champions Oncology shares are held by company insiders. Comparatively, 13.0% of Tourmaline Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Which has more risk and volatility, CSBR or TRML? Champions Oncology has a beta of 0.44, indicating that its stock price is 56% less volatile than the S&P 500. Comparatively, Tourmaline Bio has a beta of 2, indicating that its stock price is 100% more volatile than the S&P 500. Which has preferable earnings and valuation, CSBR or TRML? Champions Oncology has higher revenue and earnings than Tourmaline Bio. Champions Oncology is trading at a lower price-to-earnings ratio than Tourmaline Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioChampions Oncology$50.15M2.32-$7.28M-$0.06-140.14Tourmaline BioN/AN/A-$73.21M-$3.21-5.07 SummaryChampions Oncology beats Tourmaline Bio on 10 of the 14 factors compared between the two stocks. Get Champions Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for CSBR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CSBR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CSBR vs. The Competition Export to ExcelMetricChampions OncologyMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$122.92M$2.39B$5.47B$8.95BDividend YieldN/A1.80%5.25%4.06%P/E Ratio19.118.9827.0020.10Price / Sales2.32729.50428.95120.24Price / CashN/A159.8036.8257.86Price / Book-60.074.517.985.56Net Income-$7.28M$31.26M$3.16B$248.40M Champions Oncology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CSBRChampions Oncology4.3996 of 5 stars$8.41-13.0%$12.00+42.7%+70.9%$122.92M$50.15M19.11143News CoveragePositive NewsTRMLTourmaline Bio2.1096 of 5 stars$15.99-3.3%$49.33+208.5%+22.4%$424.84MN/A-4.9844ORKAOruka Therapeutics2.5987 of 5 stars$11.21+1.2%$40.38+260.2%N/A$414.84MN/A-2.49N/ASVRASavara2.2058 of 5 stars$2.28+3.2%$5.60+145.6%-50.3%$381.97MN/A-4.75N/APositive NewsHigh Trading VolumeRIGLRigel Pharmaceuticals2.3944 of 5 stars$18.73-3.9%$36.40+94.3%+134.1%$348.15M$179.28M9.05160HRTXHeron Therapeutics3.8245 of 5 stars$2.07-3.3%$5.00+141.5%-25.9%$326.49M$144.29M-34.50300Positive NewsAQSTAquestive Therapeutics1.244 of 5 stars$3.31+1.8%$10.14+206.4%+53.3%$322.82M$57.56M-5.61160NKTRNektar Therapeutics4.8142 of 5 stars$25.84+0.3%$84.17+225.7%+22.2%$319.60M$98.43M-2.69220Analyst ForecastHigh Trading VolumeCBIOCrescent Biopharma3.2611 of 5 stars$16.14+1.5%$25.00+54.9%N/A$310.84M$10K-0.3526News CoverageGap UpALTAltimmune2.2151 of 5 stars$3.87+10.6%$19.00+391.0%-33.5%$283.87M$20K-3.0750High Trading VolumeNATRNature's Sunshine Products1.8586 of 5 stars$14.79+2.0%$18.33+24.0%+5.5%$267.72M$454.36M27.91850High Trading Volume Related Companies and Tools Related Companies TRML Competitors ORKA Competitors SVRA Competitors RIGL Competitors HRTX Competitors AQST Competitors NKTR Competitors CBIO Competitors ALT Competitors NATR Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CSBR) was last updated on 7/9/2025 by MarketBeat.com Staff From Our PartnersA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Champions Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Champions Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CSBR Stock Alerts